Treatment of chronic hepatitis C with recombinant interferon alpha 2b.
The authors studied 70 patients affected by chronic hepatitis C where diagnosis had been made by clinical and histological tests. Intramuscular recombinant alpha 2b interferon (3 x 10(6)) was administered to 35 patients every second evening for 6 months, whereas the other 35 received aspecific treatment. Our results revealed normalization of transaminase in 57% of the patients, with distinct improvement of their clinical and histological pictures. All patients on interferon were followed up for a six-month drug free period, after which the disease reappeared in 50% of the responders.
Terranova
R
R
Department of Geriatrics, University of Catania, Italy.
Luca
S
S
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000378:metabolism; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D006526:Hepatitis C / Q000097:blood / Q000201:enzymology / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase